113-N16B
Based on 1 Customer Validation
113-N16B is an ionizable cationic lipid that can be used for the synthesis of lipid nanoparticles. 113-N16B delivers mRNA to pulmonary endothelial cells. 113-N16B can be formulated as a component into hybrid lipid nanoparticles for lung-specific delivery of mRNA (including MFSD7C mRNA and luciferase mRNA) in mice. 113-N16B is applicable to research related to lymphangioleiomyomatosis, sickle cell disease, and hemolysis-induced lung injury.
For research use only. We do not sell to patients.
- Purity : 98.0%
- Formula: C73H147N7O4S8
- Molecular Weight:1443.51
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
113-N16B (50 molar ratio; overnight) enables the formulation of hybrid LNPs when combined with cholesterol, phospholipids, and DMG-PEG2000 at a molar ratio of 50:38.5:10:1.5[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
113-N16B (LNP formulation; 0.5 mg/kg mRNA; intravenous injection; single administration) specifically delivers fLuc mRNA to the lungs of healthy Balb/c mice[1].
113-N16B formulated lipid nanoparticles (0.5 mg/kg; i.v.) enable lung-specific mRNA delivery, while 113-N16B lipid nanoparticles loaded with MFSD7C mRNA (0.5 mg/kg; i.v.; once weekly for 4 weeks) upregulate MFSD7C expression in mouse lung tissues[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ai14 Cre reporter mice (transgenic)[1]
-
Dosage:0.75 mg mRNA equiv./kg
-
Administration:i.v.; single dose
-
Result:Achieved tdTomato expression specifically localized to the lungs.
Transfected 69.6% of pulmonary endothelial cells, 7.3% of pulmonary epithelial cells, and 18.9% of pulmonary macrophages.
-
Animal Model:Balb/c mice (female, 6 to 8 weeks old)[1]
-
Dosage:0.5 mg/kg mRNA
-
Administration:i.v.; single dose
-
Result:Detected bioluminescence signals (luciferase expression) primarily in the lungs, confirming lung-targeted mRNA delivery.
-
Animal Model:HbSS-Townes, HbAA-Townes, 7Cflox/flox, 7C-/- (12-month-old HbSS-Townes/HbAA-Townes; 8-week-old 7Cflox/flox/7C-/-; PHZ-challenged 7C-/- for hemolytic lung injury model)[2]
-
Dosage:0.5 mg/kg (luciferase mRNA-loaded LNPs; single dose); 0.5 mg/kg MFSD7C mRNA per dose (MFSD7C mRNA-loaded LNPs; weekly for 4 weeks)
-
Administration:i.v. (single dose for luciferase mRNA-loaded LNPs); i.v.; weekly; 4 weeks (MFSD7C mRNA-loaded LNPs)
-
Result:Confirmed lung-specific delivery of mRNA via increased bioluminescence intensity in the lungs of mice given luciferase mRNA-loaded 113-N16B lipid nanoparticles.
Elevated MFSD7C protein expression in mouse lung tissue following administration of MFSD7C mRNA-loaded 113-N16B lipid nanoparticles.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 1443.51
-
Formula C73H147N7O4S8
-
Color Colorless to light yellow
-
SMILES
O=C(CCN(CCC(NCCSSCCCCCCCCCCCC)=O)CCN(C)CCN(CCC(NCCSSCCCCCCCCCCCC)=O)CCC(NCCSSCCCCCCCCCCCC)=O)NCCSSCCCCCCCCCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Qiu M, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proceedings of the National Academy of Sciences of the United States of America. 2022 Feb 22;119(8):e2116271119. [Content Brief]
[2]. Wang H, et al. MFSD7C protects hemolysis-induced lung impairments by inhibiting ferroptosis. Nature communications. 2024 Sep 19;15(1):8226. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)